Nkarta brings CAR NK cells into the autoimmune race

A pivot from one of the leading NK cell developers raises the question: are autoimmune diseases a better fit for CAR NK cells than cancers?

After disappointing results from a dose-finding Phase I study of CAR NK cell therapy NKX019 in patients with non-Hodgkin’s lymphoma (NHL), Nkarta Inc. (NASDAQ:NKTX) announced it is shifting focus from cancer into autoimmune diseases, and reducing headcount by 10% to extend its cash runway into 2026...